IKKβ acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis

Charles K. Pallangyo,1 Paul K. Ziegler,1 and Florian R. Greten1,2,3

Cancer-associated fibroblasts (CAFs) comprise one of the most important cell types in the tumor microenvironment. A proinflammatory NF-κB gene signature in CAFs has been suggested to promote tumorigenesis in models of pancreatic and mammary skin cancer. Using an autochthonous model of colitis-associated cancer (CAC) and sporadic cancer, we now provide evidence for a tumor-suppressive function of IKKβ/NF-κB in CAFs. Fibroblast-restricted deletion of Ikkβ stimulates intestinal epithelial cell proliferation, suppresses tumor cell death, enhances accumulation of CD4+Foxp3+ regulatory T cells, and induces angiogenesis, ultimately promoting colonic tumor growth. In Ikkβ-deficient fibroblasts, transcription of negative regulators of TGFβ signaling, including Smad7 and Smurf1, is impaired, causing up-regulation of a TGFβ gene signature and elevated hepatocyte growth factor (HGF) secretion. Overexpression of Smad7 in Ikkβ-deficient fibroblasts prevents HGF secretion, and pharmacological inhibition of Met during the CAC model confirms that enhanced tumor promotion is dependent on HGF–Met signaling in mucosa of Ikkβ-mutant animals. Collectively, these results highlight an unexpected tumor suppressive function of IKKβ/NF-κB in CAFs linked to HGF release and raise potential concerns about the use of IKK inhibitors in colorectal cancer patients.

The development of cancer is intimately regulated by the cross talk between tumor cells and the surrounding stromal cells, which are composed of inflammatory immune cells, vascular cells, and cancer-associated fibroblasts (CAFs; Hanahan and Coussens, 2012). CAFs are one of the most abundant cell types in different tumor entities; they originate from heterogeneous cell types with different molecular definitions but form a phenotypically distinct cell type (Öhlund et al., 2014). Accumulating evidence suggests CAFs can accelerate the growth and development of primary tumors, invasion, and metastasis directly and indirectly as they secrete classical growth factors (Elenbaas and Weinberg, 2001), facilitate inflammation (Andoh et al., 2007; Servais and Erez, 2013), promote angiogenesis (Orimo et al., 2005), modulate the extracellular matrix (ECM) and enhance stiffness (desmoplasia; Allen and Louise Jones, 2011), and stimulate stemness (Chen et al., 2014). They are also involved in metabolic reprogramming of the tumor microenvironment (Valencia et al., 2014), thus influencing all stages of tumorigenesis, as well as response to treatment (Crawford et al., 2009; Öhlund et al., 2014). Importantly, in colorectal cancer (CRC) a distinct set of genes specifically up-regulated in CAFs predicts poor prognosis (Calon et al., 2015). However, similarly to tumor-associated macrophages, CAFs show a high degree of plasticity and can also provide antitumorigenic functions. Genetic ablation of CAFs in preclinical models of pancreatic cancer has, surprisingly, resulted in more aggressively growing tumors and reduced survival (Özdemir et al., 2014; Rhim et al., 2014), underscoring the observation that CAFs have a much wider range of functions. It is not yet clear which factors induce and determine the different subtypes of CAFs or the signaling pathways involved between the different subtypes of CAFs and other cell types in the tumor microenvironment.

Fibroblasts respond to proinflammatory signals, including IL-1β, TNF, reactive oxygen species (ROS), and TGF-β (Pang et al., 1994; Gordon, 2000; Ogura et al., 2004; Yucel-Lindberg and Brunius, 2006; Toullec et al., 2010), and in turn produce a variety of chemokines and cytokines recruiting and activating leukocytes to sites of inflammation (Räsänen and Vaheri, 2010; Servais and Erez, 2013). Fibroblasts play a major role in facilitating the switch from acute resolving to chronic inflammation (Buckley et al., 2001; Zhang et al., 2011; Servais and Erez, 2013). Indeed, CAFs seem to express a proinflammatory NF-κB–dependent signature in tumor models of skin, mammary, and pancreatic cancer, as well as their cognate human counterparts (Erez et al., 2010). This signature consists of genes encoding proinflammatory
chemokines and cytokines such as CXCL1, CXCL2, COX2, CYR61, IL-1β, IL-6, and OPN. In transplanted tumors, recruitment of macrophages, neovascularization, and tumor cell proliferation is dependent on NF-κB signaling in co-injected CAFs. Thus, the inflammatory infiltrates and proliferating mesenchymal cells in the tumor microenvironment presumably provide essential growth factors and signaling molecules in an NF-κB–dependent manner that could further support proliferation and invasion of transformed cells (Erez et al., 2010; Jung et al., 2010; De Boeck et al., 2013).

IKKβ-dependent activation of NF-κB confers various important protumorigenic functions during colonic tumorigenesis that are dependent on tumor stage and cell type. Whereas during tumor initiation NF-κB enhances Wnt signaling in intestinal epithelial cells (IECs; Schwitalla et al., 2013a), during tumor promotion it controls cell death (Greten et al., 2004). Moreover, during tumor progression, epithelial NF-κB is required for recruitment of myeloid cells and induction of epithelial–mesenchymal transition (EMT; Schwitalla et al., 2013a). In contrast, in myeloid cells, NF-κB controls the transcription of a variety of proinflammatory cytokines that enhance tumorigenesis in a paracrine manner (Karin, 2009; SchWitalla et al., 2013a).

Whereas the diverse tumor-promoting functions of NF-κB in both malignant and inflammatory immune cells have been proven in large number of murine tumor models, direct genetic evidence for the role of NF-κB in other components of the tumor microenvironment, particularly CAFs in autochthonous tumor models, is lacking. Here, we demonstrate that NF-κB signaling in CAFs surprisingly confers antitumorigenic functions and suppresses intestinal tumor growth.

RESULTS
Lack of Ikkβ in fibroblasts increases intestinal tumor size

To target fibroblasts and CAFs throughout intestinal tumorigenesis, we employed tamoxifen-inducible Col1a2Cre-ER-T2 mice that restrict Cre-mediated recombination to all fibroblastic cells (Zheng et al., 2002). Lineage tracing in Col1a2Cre-ER-T2;Rosa26R-CAG-tdTomato (Fig. 1 A) mice confirmed recombination in subepithelial stromal cells in both untransformed intestine and colonic tumors using the azoxymethane (AOM)/dextran sulfate sodium (DSS)–induced model of colitis-associated tumorigenesis (CAC; Greten et al., 2004). Immunofluorescent staining confirmed widespread expression of collagen I and IV in Col1a2Cre-ER-T2–targeted cells in both unchallenged intestine and in AOM/DSS–induced tumors, but only partial overlap with vimentin, Fsp1, and α-SMA expression (Fig. 1 B). Recombination was not limited to the intestine and, in agreement with the original characterization of the mice (Zheng et al., 2002), we observed widespread RFP expression in other organs, including lung, liver, pancreas, kidney, and spleen (Fig. 1 C). Flow cytometric analysis confirmed that Col1a2Cre-ER-T2 mice target ~80% of all PDGFRα+ cells in the intestine, which express mesenchymal markers CD29 and CD44, but not PDGFRβ (Fig. 1, D–F). Importantly, we could not detect recombination in other stromal cells, such as CD45+ leukocytes, Ter119+ erythroid cells, CD31+ endothelial cells, and EpCAM+ epithelial cells (Fig. 1, D–F).

To examine the effect of IKKβ–dependent NF-κB activation in CAFs during intestinal tumorigenesis, we crossed conditional IkkβF/F mice with Col1a2Cre-ER-T2 mice, and Ikkβ deletion was confirmed in intestinal vimentin+ fibroblasts isolated from Col1a2Cre-ER-T2;IkkβF/F animals (termed IkkβΔFib; Fig. 1, G and H), but not in respective splenocytes (Fig. 1 I) or sorted lamina propria CD45+ cells (Fig. 1 J) upon tamoxifen administration. Loss of Ikkβ in fibroblasts did not cause any overt phenotype, and IkkβΔFib mice remained healthy when kept on a tamoxifen-containing diet without further challenge. However, when we performed the CAC model, IkkβΔFib animals were surprisingly not protected from tumor development and developed similar number of tumors as IkkβF/F littermate controls (Fig. 2 A). Moreover, absence of IKKβ in fibroblasts even strongly promoted tumor growth (Fig. 2 B), and IkkβΔFib mice developed a higher number of larger tumors (Fig. 2, C–E). Increased tumor size was accompanied by an increased proliferation rate and decreased apoptotic activity in tumor cells from IkkβΔFib mice (Fig. 2, F–I). Comparable results were also obtained in a model of sporadic tumorigenesis when we repetitively injected AOM without inducing DSS-mediated colitis (Fig. 2, J–L). Furthermore, when we assessed tumor vascularization before sacrifice on day 84 of the colitis–associated tumor model by in vivo confocal laser scanning microscopy (CLSM) blood vessel area and length in IkkβΔFib tumors were significantly increased when quantified by functional capillary density (FCD; Fig. 2, M and N). Flow cytometric analysis of stromal cells confirmed a significant increase in CD45+CD31+ endothelial cells (Fig. 2 O). To quantify the number of fibroblasts in the colon, we used the receptor tyrosine kinase PDGFRα as a marker due to its expression in ~90% of fibroblast-like cells (Erez et al., 2010). Indeed, in IkkβΔFib tumors, the number of EpCAM+CD45+PDGFRα+ fibroblasts was markedly increased (Fig. 2 P), whereas the number of CD45+ leucocytes remained unchanged (Fig. 2 Q). Immunohistochemical analysis of Ikkβ mutant tumors revealed significantly increased phosphorilation of Akt397, and Stat3705 and increased nuclear β-catenin in tumor cells (Fig. 2, R–Z). Collectively, these data suggested that lack of IKKβ in fibroblasts promotes tumorigenesis either because of an increase in the number of activated fibroblasts and/or elevated secretion of cytokines that were capable of activating Akt, Stat3, and Wnt signaling pathways that presumably control tumor cell proliferation and cell death (Cirri and Chiarugi, 2012).

Increased hepatocyte growth factor (Hgf) gene expression in Ikkβ–deficient fibroblasts

To identify possible IKKβ-regulated factors that could be responsible for the paracrine stimulation of tumor cell proliferation and angiogenesis, we performed qPCR on purified
Figure 1. Recombination in Col1a2Cre-ER<sup>T2</sup> mice is restricted to the fibroblast lineage and allows sufficient *Ikkβ* deletion in primary intestinal fibroblasts. (A) Schematic representation of the genetic strategy used to generate mice for lineage tracing of the cells undergoing recombination. Col1a2Cre-ER<sup>T2</sup> mice crossed to a reporter mouse with a stop codon flanked by Cre-recombinogenic loxP sites upstream of a reporter gene for the red fluorescent protein (RFP) Tomato, under the control of the Rosa26 promoter to generate the compound mutant mouse Col1a2Cre-ER<sup>T2</sup>;Rosa26RCAG-tdTomato. After tamoxifen administration, Cre-recombinase excises the stop codon and Rosa26 drives expression of RFP. (B) Frozen tissue sections were stained for RFP (red) and the indicated markers (green). The cells coexpressing RFP and mesenchymal markers were marked yellow and were observed in the small intestine, colon in untreated mice, and colon tumors in AOM/DSS-treated mice. Nuclei are stained blue with DAPI. Bars, 50 µm. (C) RFP expression was also widely observed in other tissues, including lung, liver, kidney, spleen, and pancreas. Nuclei are stained blue by DAPI. Bars, 100 µm. (D) Flow cytometry analysis of RFP-expressing cells in untreated Col1a2Cre-ER<sup>T2</sup>;Rosa26RCAG-tdTomato mice using markers for immune cells (CD45), epithelial cells (EpCAM), erythroid cells (Ter119), endothelial cells (CD31), and mesenchymal cells (CD29, CD44, PDGFRA, and PDGFRA<sup>B</sup>) after tamoxifen (400 mg/kg) administration for 5 d to induce cre recombination. (E–F) Representative flow cytometric analysis to quantify number of CD45<sup>+</sup>, EpCAM<sup>+</sup>, PDGFRA<sup>+</sup>, CD31<sup>+</sup>, CD29<sup>+</sup>, and CD44<sup>+</sup> cells in RFP<sup>+</sup> population. (D) Mean number of RFP<sup>+</sup> cells in respective cell populations. Data are mean ± SE; n ≥ 5. (G) Immunoblot analysis confirming purity of isolated primary intestinal fibroblasts from 6–8-wk-old *Ikkβ<sup>ΔFib</sup>* and *Ikkβ<sup>F/F</sup>* mice that were placed on a diet containing tamoxifen (400 mg/kg) for 5 d to induce cre recombination. (H–J) Immunoblot analysis of IKK<β> confirms selective deletion in fibroblasts (H) but not splenocytes (I) or lamina propria (LP) CD45<sup>+</sup> cells (J) from tamoxifen-treated *Ikkβ<sup>ΔFib</sup>* mice.
Figure 2. Fibroblast-specific IkBβ deletion promotes colon tumorigenesis. (A) Tumor incidence in IkBβ+/+ and IkBβΔFib mice at the end of the AOM/DSS regimen on day 84. Data are mean from two independent experiments ± SE; n ≥ 7; ns, not significant. (B) Mean tumor size in IkBβ+/+ and IkBβΔFib mice. Data are mean ± SE; n ≥ 7; ***; P < 0.0001 by Student's t test. (C) Histogram showing size distribution of tumors in IkBβ+/+ and IkBβΔFib mice. (D and E) Overview of representative sections of the Swiss rolls that were used for tumor counting; bars, 1 mm. (F-H) Immunohistochemical analysis of BrdU incorporation (F and G) and proliferation index (H) in tumor epithelial cells from IkBβ+/+ and IkBβΔFib mice. Bars, 50 µm. (I) Quantification of cleaved caspase 3 staining for the apoptotic index in tumor epithelial cells from IkBβ+/+ and IkBβΔFib mice. (J) Tumor incidence in IkBβ+/+ and IkBβΔFib mice at the end of the sporadic tumor regimen (six weekly AOM injections without additional DSS administration) at week 22. Data are mean from two independent experiments ± SE; n ≥ 9; ns, not significant. (K) Mean tumor size in IkBβ+/+ and IkBβΔFib mice. Data are mean ± SE; n ≥ 9; **; P < 0.005 by Student's t test. (L) Quantification of the prolifer-
expression levels between the different genotypes. However, transcription of genes encoding classical NF-κB-dependent proinflammatory cytokines, such as Il6, Cox2, Cxcl1, and Cxcl12 was reduced, whereas Il-1β, Cxcl2, and Cxcl5 expression levels remained unchanged (Fig. 3 A). CAFs are the main drivers of stromal TGF-β–driven programs associated with poor clinical outcome in CRC (Calon et al., 2014). We therefore examined gene expression levels of Tgfb1, Tgfb2, and Tgfb3, but could not detect any relevant changes in their expression levels between the different genotypes. However, Smad7 and Smurf1 coding for negative regulators of TGF-β signaling, and the former known to be transcriptionally regulated by NF-κB (Bitzer et al., 2000; Freudlsperger et al., 2013), were markedly down-regulated in the absence of IKKβ, causing up-regulation of several TGF-β–controlled targets, including Decorin, Ctgf, Cald1, Postn, Il11, and Igfbp7 (Fig. 3 A). Importantly, however, Hgf mRNA coding for one of the most prominent promitogenic factors secreted by CAFs was markedly up-regulated (Fig. 3 A). HGF is a pleiotropic cytokine produced mainly by fibroblasts, and it acts on adjacent epithelial and endothelial cells by binding to cell surface c-Met receptor, promoting cell survival, proliferation, and migration via Akt, Stat3, and Wnt activation (Hoot et al., 2010; Nakamura et al., 2011; Organ and Tsao, 2011). HGF is also known to be a potent angiogenic factor, stimulating endothelial cell recruitment, motility, and growth (Bussolino et al., 1992; Trusolino et al., 2010). Overexpression of HGF or its receptor c-Met is seen in many tumors, including CRC, and is associated with poor prognosis (Stein et al., 2009; Liu et al., 2012). Accumulating evidence suggests a role of CAFs, and particularly HGF in maintaining the cancer-stem cell niche (De Wever et al., 2008; Vermeulen et al., 2010; Quante et al., 2011). We therefore analyzed sorted EpCAM+ tumor cells and detected consistent up-regulation of various cancer stem cell markers, including Ascl2, Tmsf19, Sox2, Sox9, EphB2, EphB3, Dclk1, and Lgr5, as well as EMT master regulators Snail and Slug in tumor cells derived from IkkβΔFib mice, indicating increased stemness (Fig. 3 B). This strongly supported the possibility that the observed phenotype in IkkβΔFib mice regarding increased IEC proliferation, increased angiogenesis, and stemness could be explained by elevated HGF expression in Ikkβ-deficient fibroblasts.

**Enhanced IEC proliferation in response to acute colitis in IkkβΔFib mice**

To examine whether the decreased expression of proinflammatory cytokines in Ikkβ-deficient fibroblasts would affect the outcome of DSS-induced colitis, we examined animals of both genotypes on day 15 of the AOM/DSS model during the acute phase of inflammation. However, loss of Ikkβ in fibroblasts did not affect the initial DSS-induced epithelial cell death (not depicted), and therefore the extent of inflammation determined by weight loss (Fig. 4 A), histological damage, and number of ulcerations (Fig. 4, B and C) was indifferent between both genotypes. Whereas Tnfa and Il1b mRNA levels were not altered in IkkβΔFib whole mucosa, Il6 and Cxcl1 expression was decreased (Fig. 4 D). Importantly, despite no differences in the mRNA levels of Tgfb1, Tgfb2, and Tgfb3, already at this early time point Hgf and Ftg1 and bfgf gene expression was markedly elevated in mucosa of DSS-challenged IkkβΔFib mice (Fig. 4 D). This was paralleled by increased epithelial Met phosphorylation in IkkβΔFib mice (Fig. 4, E–H), which presumably was responsible for promoting IEC proliferation (Fig. 4, I–K). Myofibroblasts play an active role in regulation of the type and duration of leukocyte infiltration after acute inflammation (Pilling et al., 1999; Servais and Erez, 2013), and deregulation of this process can lead to inappropriate immune responses promoting tumorigenesis (Östman and Augsten, 2009). Fibroblasts can also suppress inflammation by inducing FoxP3+ regulatory T cell proliferation directly by secreting TGF-β into the microenvironment (Yang et al., 2010) or in an IL-15–dependent manner (Clark and Kupper, 2007). We therefore isolated and analyzed the lamina propria–infiltrating immune cell populations during DSS-induced colitis by flow cytometry. Although we found no differences in the relative numbers of CD45+ EpCAM+, CD31+, and PDGFRα+ cells (Fig. 5 A), or CD11b+F4/80+, CD11b+Gr-1+, and CD11b+CD11c+ myeloid cells (Fig. 5 B), we found a significant increase in the relative numbers of CD3+CD4− T cells, as well as CD4+Foxp3+ regulatory T cells in the IkkβΔFib group. There was also a slight increase in CD4+IFNy+ T cells, but it was not significant, the levels of CD4+IL17a+ T cells remained unchanged between the two groups (Fig. 5 C).

**Enhanced HGF secretion in the absence of Ikkβ depends on Smad7 down-regulation**

To examine whether elevated Hgf transcription was a direct cell autonomous effect of Ikkβ deletion in fibroblasts or an...
indirect consequence by an altered microenvironment, we examined HGF production in purified ex vivo cultured intestinal fibroblasts. To this end, we purified intestinal fibroblasts from tumor-bearing IkkβΔFib and IkkβF/F mice, as well as on day 15 of the CAC regimen. Fibroblasts were seeded in 24-well plates and cultured to 80% confluence. After 24 h of serum starvation, they were either left untreated or stimulated with TGFβ (10 ng/ml) or EGF (10 ng/ml) separately or simultaneously over a period of up to 72 h. Independent of the time point, whether cells had been isolated or the stimulus that had been applied, after DSS-induced colitis or AOM/DSS-induced tumorigenesis Ikkβ-deficient fibroblasts secreted up to fourfold more HGF compared with cells from littermate controls (Fig. 6, A and B). Similar effects were observed when cells were treated with PMA (unpublished data). These results clearly indicated that IKKβ directly suppresses HGF production in a cell autonomous manner. So far, NF-κB has not been shown to directly bind to the Hgf promoter, yet considering the clear induction by TGFβ in Ikkβ-deficient fibroblasts and the decreased Smad7 expression in Ikkβ-deficient fibroblasts (Fig. 3 A), we speculated that IKKβ/NF-κB may affect HGF secretion via Smad7-dependent regulation of TGFβ signaling. Thus, using a retroviral approach, we overexpressed Smad7 in Ikkβ-deficient intestinal fibroblasts (Fig. 6 C), which indeed completely prevented TGFβ- and EGF-dependent HGF secretion in Ikkβ-deficient fibroblasts compared with cells that had been transduced with a GFP-control retrovirus (Fig. 6 D).

**Blocking c-Met signaling prevents tumor-promoting effects of Ikkβ-deficient fibroblasts**

To finally confirm that enhanced HGF secretion by Ikkβ-deficient fibroblasts was responsible for the observed increase in tumor growth, we inhibited c-Met activation by feeding mice of both genotypes a diet containing a selective c-Met inhibitor INCB28060 (capmatinib; Liu et al., 2011) during the recovery phase after each DSS cycle (Fig. 7 A). Capmatinib did not affect tumor incidence, but blocked tumor

---

**Figure 3. Up-regulation of TGFβ-dependent transcriptional targets in Ikkβ-deficient CAFs.** (A) Relative expression levels of indicated mRNAs isolated from sorted PDGFRα+ CAFs from AOM/DSS-induced tumor tissues of IkkβF/F and IkkβΔFib mice and analyzed by real-time PCR. Data are mean from two independent experiments ± SE; n ≥ 4. (B) Relative expression levels of indicated mRNAs isolated from sorted EpCAM+ tumor cells from AOM/DSS-induced tumor tissues of IkkβF/F and IkkβΔFib mice and analyzed by real-time PCR. Data are mean ± SE; n ≥ 4.
Figure 4. Ikkβ-deficiency in fibroblasts does not affect inflammatory response, but stimulates IEC proliferation after acute DSS-induced colitis. (A) Weight curves of Ikkβ^f/f and Ikkβ^ΔFib mice during first cycle of acute colitis. Data are mean from two independent experiments ± SEM. n ≥ 7 mice per group. (B and C) Histological damage (B) and number of ulcerations (C) in Ikkβ^f/f and Ikkβ^ΔFib mice after the first cycle of DSS on day 15 of the AOM/DSS regimen. Data are mean ± SE; n ≥ 7 mice per group. (D) Relative expression levels of indicated mRNAs isolated from whole mucosa of Ikkβ^f/f and Ikkβ^ΔFib mice on day 15 of the CAC model and analyzed by real-time PCR. Data are mean ± SE; n ≥ 7. Data are mean from two independent experiments (E–G) Immunofluorescence staining of p-Met in whole mucosa (E and F) and immunoblot analysis of p-Met in IEC (G) of Ikkβ^f/f and Ikkβ^ΔFib mice on day 15 of the CAC model. (H) Quantification of immunoblot analysis using Image J. Bars, 20 µm. (I–K) Immunohistochemical analysis of BrdU incorporation (I and J) and proliferation index (K) in IEC (K) of Ikkβ^f/f and Ikkβ^ΔFib mice on day 15 of the CAC model. Bars, 20 µm. *, P < 0.05.
growth in control animals (Fig. 7 B). However, in IkkβΔFib mice, c-Met inhibition was even more apparent and capmatinib suppressed both tumor incidence, as well as tumor size. Two out of the eight treated IkkβΔFib mice (25%) did not develop any adenomas, and capmatinib prevented the enhanced tumor growth in untreated IkkβΔFib mice. Consequently, tumor size was now comparable to those in capmatinib-treated control animals. Moreover, capmatinib blocked angiogenesis in IkkβΔFib mice to levels observed in IkkβF/F tumors (Fig. 7 D) and normalized the number of regulatory T cells in the mucosa during the acute inflammatory response (Fig. 7 H). In line with decreased tumor growth, activation of Stat3 and Akt and expression of nuclear β-catenin were down-regulated in the presence of capmatinib in IkkβΔFib mice (Fig. 7, E–G). Collectively, these data confirmed that, indeed, enhanced HGF secretion by Ikkβ-deficient fibroblasts accounted for the enhanced tumor promotion in IkkβΔFib mice by regulating tumor cell proliferation, cell death, angiogenesis, and T cell polarization.

**DISCUSSION**

Canonical IKKβ-dependent NF-κB activation is considered a key signaling pathway linking inflammation and tumorigenesis (Greten et al., 2004). In tumor cells, as well as inflammatory immune cells, NF-κB controls a variety of functions that ultimately favor all stages of tumorigenesis (Karin, 2009). In line with this notion, CAFs in pancreatic, skin, and mammary cancer express a proinflammatory NF-κB signature, and expression of dominant-negative IKKβ in cotransplanted CAFs inhibited tumorigenesis (Erez et al., 2010). Here, we report the unexpected observation that Ikkβ in Col1a2-expressing fibroblasts suppressed tumor growth in a model of CAC. This was strictly dependent on elevated HGF secretion, which stimulated cell proliferation, increased angiogenesis, and induced T reg cell polarization during colitis. Interestingly, pronounced HGF production was not limited to inflammation-associated tumorigenesis. We obtained similar results when sporadic colon tumors were initiated by AOM without additional DSS-triggered inflammation. The MAPK Tpl2 has been suggested to be involved in the upstream activation of NF-κB (Vougioukalaki et al., 2011). Interestingly, mice that lack Tpl2 in ColVI-expressing intestinal myofibroblasts show a very similar HGF-dependent phenotype in the CAC model, but not in an inflammation-independent model (Koliaraki et al., 2012). Surprisingly, however, IKKβ deletion in ColVI-expressing cells causes tumor inhibition in the CAC model, as discussed by Koliaraki and Kollias in this issue. Considering that Col1a2 targets nearly 80% of PDGFRα+ cells, thus recombining in a much larger fraction of fibroblasts, raises the possibility that IKKβ/NF-κB may have distinct functions in different fibroblast subpopulations, possibly explaining the discrepancy between these results, as well as the previously reported findings when CAFs had been co-injected in xenografts of pancreatic and mammary cancer (Erez et al., 2010). Furthermore, the diametric opposite results in these two CAC studies here underscores the notion that CAFs represent much more than just one single cell type and provide strong evidence for the importance of different subpopulations within this cell lineage. Considering this high degree of plasticity in fibroblasts, NF-κB signaling may be differently affected or confer distinct functions depending on the respective activation status of CAF subpopulations.
Nevertheless, evidence emerging from other mesenchymal cell types, including adipocytes, macrophages, and muscle-derived stem cells, NF-κB negatively regulates Hgf transcription in response to proinflammatory stimuli (Yin et al., 2014; Proto et al., 2015).

Our data further highlights the great importance of HGF for colorectal carcinogenesis. HGF is a potent and pleiotropic growth factor with important roles in regeneration and homeostasis in many adult tissues (Trusolino et al., 2010). It is secreted by mesenchymal cells, especially fibroblasts in a preform, and requires cleavage by extracellular proteases to produce the biologically active heterodimer, which can then bind to its receptor c-Met and activate downstream signaling. The C-terminal motif of c-Met contains docking sites for numerous downstream signaling pathways, including PI3K, GAB1, phospho-lipase Cγ1, and STAT3 (Ponzetto et al., 1994; Trusolino et al., 2010), leading to cell proliferation, reduced apoptosis, and enhanced angiogenesis. HGF has also been identified as the stromal factor responsible for maintenance of the cancer stem cell niche (Vermeulen et al., 2010) and aberrant activation of this signaling pathway correlates with a poor prognosis in CRC (Arlt and Stein, 2009). Indeed, sorted tumor cells from IkkβΔFib mice expressed higher levels of several stem cell and EMT markers. Interestingly, HGF seemed to be also responsible for T reg cell polarization during acute colitis considering the normalization upon capmatinib administration. This is consistent with findings in preclinical models of autoimmune diseases such as osteoarthritis, autoimmune myocarditis, and in CNS demyelinating autoimmune diseases when HGF promoted T reg cell accumulation by suppressing dendritic cell function (Okunishi et al., 2007; Benkhoucha et al., 2010).

One important upstream regulator of HGF secretion in CAFs is TGF-β. TGF-βRII–deficient fibroblasts secrete elevated levels of HGF, and fibroblast-specific deletion of TGF-βRII triggers development of spontaneous prostate and forestomach cancer (Bhowmick et al., 2004). In squamous cell carcinoma (SCC), it has been shown that HGF signaling is the central mediator of myofibroblast-derived paracrine signaling promoting tumorigenesis after TGF-β-dependent fibroblast to myofibroblast conversion. SCC cells produce TGF-β, thus activating adjacent fibroblasts, and the resulting myofibroblasts produced more HGF than their precursors, which significantly promoted tumor invasion (Lewis et al., 2004). We found TGFβ1 induces HGF secretion at significantly higher levels after genetic ablation of NF-κB signaling, and we could demonstrate that SMAD7 plays a key role in the control of HGF secretion in murine CAFs. SMAD7 negatively regulates TGFβ signaling, whereas it is transcriptionally regulated by NF-κB (Baugé et al., 2008; Yan et al., 2009; Freudlsperger et al., 2013). Cross talk between NF-κB and TGFβ signaling via SMAD7 has already been described in head and neck cancer (Freudlsperger et al., 2013), osteosarcoma (Elsieev et al., 2006), and breast and gastric cancers (Hong et al., 2007).
Importantly, the enhanced TGFβ signaling in IKKβ-deficient CAFs did not just promote HGF release, but also led to the up-regulation of several other TGFβ-dependent target genes that have recently been identified to predict poor prognosis in CRC patients (Calon et al., 2015). Thus, in addition to the previously identified negative regulation of IL-1β secretion causing increased susceptibility to sepsis when inhibiting IKKβ (Greten et al., 2007), our data here raise additional concern regarding the use of specific IKKβ inhibitors for the treatment of CRC. However, considering that these effects seem to be restricted to CAFs, and that in intestinal tumor cells and myeloid cells NF-κB clearly confers tumor-promoting functions (Greten et al., 2004; Schwitalla et al., 2013a,b), it remains to be determined what net effect pharmacological IKKβ inhibition may have.

MATERIALS AND METHODS

Mice. Col1a2-creER<sup>T2</sup> mice and Rosa26R-TdTomato reporter mice were purchased form The Jackson Laboratory. Ikkβ<sup>F/F</sup> have been described previously (Greten et al., 2004). All mice including cre-negative littermate controls were crossed on a FVB background for at least four generations and in all experiments littermate controls were used. To ensure sustained recombination mice were kept on a diet containing tamoxifen (400 mg/kg; LASvendi) throughout the duration of the CAC model. AOM/DSS-induced tumor-
genesis was performed essentially as previously described (Bollrath et al., 2009). 10 mg/kg AOM (Sigma-Aldrich) was injected i.p. at day 0, 5 d before mice received 2% DSS (MP Biosystems) in the drinking water for 5 d, followed by 16 d of regular water, which was repeated twice. Severity of colitis was assessed histologically as described before (Eckmann et al., 2008). The c-Met inhibitor INCIB28060 (capmatinib) was purchased from Selleckchem and incorporated (18 mg/kg) along with tamoxifen (400 mg/kg) into rodent diet AIN-76A (Research Diets, Inc.). Control groups received tamoxifen containing AIN-76A diet only. All experiments were approved by the Regierungspräsidium Darmstadt.

**Histology and immunohistochemistry.** Colons were removed, opened longitudinally, rolled as swiss rolls, and fixed in 4% PFA overnight at 4°C. Tissues were subsequently dehydrated and paraffin embedded. 4 µm sections were used for histological analysis. For immunohistochemistry: after deparaffinization and rehydration of the tissue, antigen retrieval was done by incubating the tissue section in 10 mM sodium citrate buffer, pH 7.4 in sub boiling temperature in the microwave for 20 min. After cooling and washing the tissue, the endogenous peroxidase activity was quenched with 3% hydrogen peroxide for 10 min at room temperature. Sections were blocked with 5% normal donkey serum in PBS containing 1% BSA and 0.1% Tween-20 for 1 h at room temperature. Endogenous avidin and biotin were blocked using the avidin–biotin kit (Vector Labs), following the manufacturer’s instructions. The following primary antibodies were used: α-BrdU (MCA2060; AbDSerotec), α-cleaved caspase 3 (9661S; Cell Signaling Technology), α-p-Stat3Ser705 (9145; Cell Signaling Technology), α-pAktSer473 (3787S; Cell Signaling Technology), α-β-catenin (06–734; EMD Millipore), α-p-Met (ab5662; Abcam), α-E-cadherin (610182; BD). To determine cell proliferation, mice were injected i.p. with 75 mg/kg BrdU (Sigma-Aldrich) 90 min before sacrifice. Quantification of positive nuclei was done using eSlide manager version 12.0.1.5027 after image acquisition by the Aperio Scanscope XT (Leica).

**Isolation of primary intestinal fibroblasts.** Colons were harvested and thoroughly washed with PBS containing 100 U/ml penicillin/streptomycin and 50 µg/ml gentamicin sulfate. For isolation of fibroblasts on day 15 of the AOM/DSS regimen, the entire distal one-third of the colon was harvested. For isolation of CAFs only tumor tissue was harvested and used for cell separation. After repeated washing, tissue was minced and digested in 1 mg/ml collagenase I (Sigma-Aldrich), 1 mg/ml Dispase II (Roche), 50 µg/ml DNase (Sigma-Aldrich) in 10 ml RPMI containing 2% FBS for 60 min. Supernatant was filtered through a 40-µm cell strainer, and the single-cell suspension was plated on T75 flasks. Cells were cultured in complete DMEM containing 10% FCS, 1% glutamax, 1% nonessential amino acids, 1% penicillin/streptomycin. Cells between the fourth and eighth passage were used for experiments. Cell stimulation was done after a 24-h serum starvation period and using DMEM containing only 1% PenStrep (Gibco), 1% glutamax (Gibco), and 1% nonessential Amino Acids (Gibco). For RNA analysis, cells were sorted by flow cytometry and directly collected in RNA lysis buffer.

**RNA and qPCR.** RNA from tissue/cells was harvested using RNAeasy mini kit (QIAGEN). SuperScript II reverse transcription (Life Technologies) was used for cDNA synthesis. qRT-PCR was then performed on a StepOne plus Real-Time PCR detection system (Applied Biosystems) using the SYBR Green PCR Master Mix (Roche) according to the manufacturer’s instructions. Forward and reverse primers were added at a concentration of 0.2 pmol/ml in a final volume of 20 µl. The primers used are listed in Table S1.

**Protein analysis.** Immunoblotting was done using standard procedures. Protein lysates from cell pellets/tissue was separated using SDS-gel electrophoresis and transferred onto PVDF membranes. They were blocked with 5% milk in PBS containing 0.1% Tween 20 and incubated with specific antibodies. The following primary antibodies were used: α-p-Met (ab5662; Abcam) and α-SMAD-7 (sc-11392; Santa Cruz Biotechnology, Inc.). Secreted HGF in the supernatants was measured using an ELISA kit (R&D Systems) according to manufacturer’s instructions.

**Flow cytometry.** Flow cytometry was performed using BD FACSCanto II flow cytometer, and analysis was done using FlowJo software, v8.8.6 (Tree Star). A schematic representation of the preparation and gating strategy is provided in. Fig. S1. Colon was harvested, washed thoroughly, minced using sterile scalpels, and digested in 1 mg/ml collagenase I (Sigma-Aldrich), 1 mg/ml Dispase II (Roche 04942078001), 50 µg/ml DNase (Sigma-Aldrich) in 10 ml of RPMI containing 2% FBS for 60 min. The supernatant was passed through a 40-µm cell strainer and the single cell suspension was stained using following antibodies: α-CD3 APC-eFluor 780(47–0032), α-CD4 eFluor 450(48–0041), α-CD8a PerCP-Cyanine5.5 (45–0081), α-IFN-γ Alexa Fluor 488(53–7311), α-IL-4 PE-Cyanine7(25–7041), α-IL-17A APC (17–7177), α-Foxp3 PE (12–4771), α-CD11b APC-eFluor 780 (47–0112), α-CD11c FITC (11–0114), α-F4/80 APC (17–4801), α-Ly-6G (Gr-1) PE-Cyanine7(25–5931), α-PDGFα PE (12–1401–81), Fixable Viability Dye eFluor 560 (65–0866; all antibodies from eBioscience). For in vitro stimulation and intracellular staining, cells were plated on 6-well plates, stimulated with PMA (20 ng/ml) and ionomycin (1 µg/ml) in RPMI medium with 10% FCS and 1% PS and 1% Brefeldin A (eBioscience) for 5 h. Cells were then harvested and stained with specific antibodies for the surface markers and a fixable viability dye. The cells were then fixed using IC fixation buffer (eBioscience) and stained with antibodies for the intracellular stains in 1× wash/perm buffer.
Confocal laser endomicroscopy. Endoscopic imaging and quantification of angiogenesis was done using probe-based confocal laser endomicroscopy (CLE; CellVizio; Mauna Kea Technologies), enabling real-time in-vivo microscopy of mucosal surfaces. Anesthetized mice were injected with 10 µl of 1% fluorescein i.v. and, immediately after, examined with a miniprobe (Mauna Kea Technologies). CLE images were recorded as grayscale video sequence files at 12 frames per second for ten minutes 10 min after fluorescein injection. At least 10 images per tumor were used to calculate the FCD of the tumor areas using the CellVizio software.

Retrovirus production and retroviral transduction. To prepare retroviral supernatants, pBabe Flag Smad7 plasmid (a gift from R. Derynck, University of California, San Francisco, CA; plasmid #14836; Addgene) was transfected into Phoenix-Eco packaging D2clone (Invitrogen) and into 293T cells (a gift from R. Plowman, University of Melbourne, Australia) using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s instructions. The virus-containing supernatant was collected 48 h after transfection. For retroviral transduction, one degree fibroblasts were plated in 6-well dishes at 2 × 10⁵ cells (40–60%) confluence. After filtering and centrifugation, the virus supernatant containing 4 µg/ml polybrene was added and the cells were cultured for 48 h at 37°C. Selection of infected clones was done with puromycin. Control fibroblasts were transduced with eGFP retrovirus.

Statistics. Data are expressed as mean ± SEM. Statistical analysis methods were used standard two-tailed Student’s t test for two datasets and ANOVA, followed by Bonferroni post-hoc test for multiple datasets using Prism4 (GraphPad). P-values ≤ 0.05 were considered significant.

Online supplemental material. Fig. S1 shows scheme of cell fractionation and confirmation of cell purity. Table S4, available as an Excel file, shows sequences of oligonucleotides used in real-time PCR. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20150576/DC1.

ACKNOWLEDGMENTS

We thank Natalia Delis, Kathleen Mohs, Christin Dannell, Eva Rudolf, and Petra Dinse for expert technical assistance.

This work was supported in part by the LOEWE Center for Cell and Gene Therapy Frankfurt (III L 4-518/17.004) and institutional funds from the Georg-Speyer-Haus, as well as grants from the Deutsche Forschungsgemeinschaft (Gr1916/11-1) and the ERC (ROS-281967) to F.R. Greten.

The authors declare no competing financial interests.

Submitted: 30 March 2015
Accepted: 3 November 2015

REFERENCES

Allen, M., and J. Louise Jones. 2011. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol. 223:162–176. http://dx.doi.org/10.1002/path.2803

Andoh, A., S. Bamba, M. Brittan, Y. Fujiyama, and N.A. Wright. 2007. Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacia. Ther. 114:94–106. http://dx.doi.org/10.1016/j.pharmthera.2006.12.004

Ariti, F., and U. Stein. 2009. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int. J Biochem. Cell Biol. 41:2356–2359. http://dx.doi.org/10.1016/j.biocell.2009.08.001

Baugé, C., J. Attia, S. Leclercq, J.-P. Pujol, P. Galéra, and K. Bounouidiene, 2008. Interleukin-1β up-regulation of Smad7 via NF-κB activation in human chondrocytes. Arthritis Rheum. 58:221–226. http://dx.doi.org/10.1002/art.23154

Benkhoucha, M., M.-L. Santiago-Rabé, G. Schneider, M. ChoufBen, H. Funakoshi, T. Nakamura, and P.H. Lalive. 2010. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+ FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci. USA. 107:6424–6429. http://dx.doi.org/10.1073/pnas.0912437107

Blomqvist, N.A., A. Chytil, D. Plieth, A.E. Gorska, N. Dumont, S. Shappell, M.K. Washington, E.G. Neilson, and H.L. Moses. 2004. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 303:848–851. http://dx.doi.org/10.1126/science.1099922

Bitzer, M., G. von Gersdorff, D. Liang, A. Dominguez-Rosales, A.A. Beg, M. Rokjand, and E.P. Böttger. 2006. A mechanism of suppression of TGF-β/SMAD signaling by NF-κB/RelA. Genes Dev. 14:187–197.

Bollrath, J., T.J. Phesse, V.A. von Burstn, T. Putoczki, M. Bennecke, T. Bateman, T. Nebelsiek, T. Lundgren-May, O. Canli, S. Schwitalla, et al. 2009. gpl30-mediated Stat3 activation in enterocytes regulates cell cycle and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 15:91–102. http://dx.doi.org/10.1016/j.ccr.2009.01.002

Buckley, C.D., D. Pilling, J.M. Lord, A.N. Akbar, D. Scheel-Toellner, and M. Salmon. 2001. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol. 22:199–204. http://dx.doi.org/10.1016/S1471-4906(01)01863-4

Bussolin, F., M.F. Di Renzo, M. Ziche, E. Bocchietto, M. Olivero, L. Naldini, G. Gaulino, L. Tamagnone, A. Cofer, and PM. Comoglio. 1992. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 119:629–641. http://dx.doi.org/10.1083/jcb.119.3.629

Calon, A., D.V.F. Tauroliell, and E. Ballie. 2014. TGF-β in CAF-mediated tumor growth and metastasis. Semin. Cancer Biol. 25:15–22. http://dx.doi.org/10.1016/j.semcancer.2013.12.008

Calon, A., E. Lonardo, A. Berenguer-Llergo, E. Espinet, X. Hernando-Mombonna, M. Iglesias, M. Sevillano, S. Palomo-Ponce, D.V.F. Tauroliell, D. Byrom, et al. 2009. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 41:2356–2359. http://dx.doi.org/10.1038/ng.3225

Chen, W.-J., C.-C. Ho, Y.-L. Chang, H.-Y. Chen, C.-A. Lin, T.-Y. Ling, S.-L. Yu, S.-Y. Yuan, Y.-J. Chen, C.-Y. Lin, et al. 2014. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat. Commun. 5:3472.

Curir, P., and P. Chiarugi. 2012. Cancer-associated fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 31:195–208. http://dx.doi.org/10.1007/s10555-011-9340-x

Clark, R.A., and T.S. Kupper. 2007. IL-15 and dermal fibroblasts induce proliferation of natural regulatory T cells isolated from human skin. Blood. 109:194–202. http://dx.doi.org/10.1182/blood-2006-02-002873

Crawford, Y., I. Kasman, L. Yu, C. Zhong, X. Wu, Z. Modrusan, J. Kaminker, and N. Ferrara. 2009. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 15:21–34. http://dx.doi.org/10.1016/j.ccr.2008.12.004

De Boeck, A., A. Hendrix, D. Maynard, M. Van Boeckstal, A. Daniëls, P. Pauwels, C. Gespach, M. Bracke, and O. De Weyer. 2013. Differential secretome analysis of cancer-associated fibroblasts and bone marrow-
Hanahan, D., and L.M. Coussens. 2012. Accessories to the crime: functions of Karin, M. 2009. NF-κβ.

Greten, F.R., L. Eckmann, T.F. Greten, J.M. Park, Z.-W. Li, L.J. Egan, M.F. Eckmann, L., T. Nebelsiek, A.A. Fingerle, S.M. Dann, J. Mages, R. Lang, S. Elenbaas, B., and R.A. Weinberg. 2001. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264:169–184. Eliseev, R.A., E.M. Schwarz, M.J. Zuscik, R.J. O'Keefe, H. Drissi, and R.N. Rosier. 2006. Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by FnKβ. Exp. Cell Res. 312:40–50. Erez, N., M. Truitt, P. Olson, S.T. Arron, and D. Hanahan. 2010. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-κβ-dependent manner. Cancer Cell. 17:135–147.

Freudlenger, C., Y. Bian, S. Contag Wise, J. Burnett, J. Coupar, X. Yang, Z. Chen, C. Van Waes, J. Burnett, J. Coupar, et al. 2013. TGF-β and NF-κβ signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers. Oncogene. 32:1549–1559. http://dx.doi.org/10.1038/onc.2013.127.

Gordon, J.R. 2000. TGFβ1 and TNFα secreted by mast cells stimulated via β2 and TNF-α receptor 1 and 2 and TNF-α mediate stromal cell rescue of T cells from apoptosis. J. Exp. Med. 215:1053–1056. Hori, M., M. Hayashi, S. Kaneko, Y. Saito, S. Osaka, M. Oshimi, A., P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naem, V.J. Carey, A.L. Richardson, and R.A. Weinberg. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. http://dx.doi.org/10.1016/j.cell.2005.02.034

Östman, A., and M. Augsten. 2009. Cancer-associated fibroblasts and tumor growth—bystanders turning into key players. Curr. Opin. Genet. Dev. 19:67–73. Özdemin, B.C., T. Pentaehoa-Hoang, J.L. Carstens, X. Zheng, C.-C. Wu, T.R. Simpson, H. Lakhi, H. Sugimoto, C. Kahler, S.V. Noetkiy, et al. 2014. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 25:719–734. http://dx.doi.org/10.1016/j.ccr.2014.06.005

Pang, G., L. Couch, R. Batay, R. Clancy, and A. Cripps. 1994. GM-CSF, IL-1α, IL-1β, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1α and TNF-α. Clin. Exp. Immunol. 96:437–443. Pilling, D., A.N. Akbar, J. Girdlestone, C.H. Orteu, N.J. Borthwick, N. Amfi, D. Scheel-Toellner, C.D. Buckley, and M. Salmon. 1999. Interferon-β mediates stromal cell rescue of T cells from apoptosis. Eur. J. Immunol. 29:1041–1050. http://dx.doi.org/10.1002/1073-0286(C)200401023

Koliarakis, V., M. Pasparakis, and G. Kollias. 2015. IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J. Exp. Med. http://dx.doi.org/10.1084/jem.20150576

Lewis, M.P., K.A. Lygoe, M.L. Nystrom, W.P. Anderson, P.M. Speight, J.F. Marshall, and G.J. Thomas. 2004. Tumour-derived TGF-β1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br. J. Cancer. 90:822–832. http://dx.doi.org/10.1038/sj.bjc.6601611

Liu, X., Q. Wang, G. Yang, C. Marando, H.K. Koblish, L.M. Hall, J.S. Friedman, E. Belshad, R. Wynn, Y. Li, et al. 2011. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFRe and HER-3. Clin. Cancer Res. 17:7127–7138. http://dx.doi.org/10.1158/1078-0432.CCR-11-1157

Liu, Y., Q. Li, and L. Zhu. 2012. Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori. 98:105–112.
Proto, J.D., Y. Tang, A. Lu, W.C.W. Chen, E. Stahl, M. Poddar, S.A. Beckman, P.D. Robbins, L.J. Niedernihofer, K. Imbrogno, et al. 2015. NF-κB inhibition reveals a novel role for HGF during skeletal muscle repair. Cell Death Dis. 6:e1730.

Quante, M., S.P. Tu, H. Tomita, T. Gonda, S.S.W. Wang, S. Takashi, G.H. Baik, W. Shibata, B. Dprete, K.S. Betz, et al. 2011. Bone marrow–derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 19:257–272. http://dx.doi.org/10.1016/j.ccr.2011.01.020

Rasinen, K., and A. Valheri. 2010. Activation of fibroblasts in cancer stroma. Exp. Cell Res. 316:2713–2722. http://dx.doi.org/10.1016/j.yexcr.2010.04.032

Rhim, A.D., P.E. Oberstein, D.H. Thomas, E.T. Mirek, C.F. Palermo, S.A. Sastra, E.N. Dekleva, T. Saunders, C.P. Becerra, I.W. Tattersall, et al. 2014. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 25:735–747.

Schwitalla, S., A.A. Fingerle, P. Cammareri, T. Nebelsiek, S.I. Göktuna, P.K. Ziegler, O. Canli, J. Heijnans, D.J. Huels, G. Moreaux, et al. 2013a. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell. 152:25–38. http://dx.doi.org/10.1016/j.cell.2012.11.014

Schwitalla, S., P.K. Ziegler, D. Horst, V. Becker, I. Kerle, Y. Begus-Nahrmann, A. Lechel, K.L. Rudolph, R. Langer, J. Slotta-Huspenina, et al. 2013b. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell. 23:93–106. http://dx.doi.org/10.1016/j.ccr.2013.06.006

Servais, C., and N. Erez. 2013. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J. Pathol. 229:198–207.

Stein, U., W. Walth, F. Arlt, H. Schwabe, J. Smath, I. Fichtner, W. Birchmeier, and P.M. Schlag. 2009. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat. Med. 15:59–67. http://dx.doi.org/10.1038/nm.1889

Toullec, A., D. Gerard, G. Despouy, B. Bourachot, M. Cardon, S. Lefort, M. Richardson, G. Rigail, M.C. Parrini, C. Lucches, et al. 2010. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2:211–230. http://dx.doi.org/10.1002/emmm.201000073

Trusolino, L., A. Bertotti, and P.M. Comoglio. 2010. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11:834–848.

Valencia, T., J.Y. Kim, S. Abu-Baker, J. Moscat-Pardos, C.S. Ahn, M. Reina-Campos, A. Duran, E.A. Castilla, C.M. Metallo, M.T. Diaz-Meco, and J. Moscat. 2014. Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell. 26:121–135. http://dx.doi.org/10.1016/j.ccr.2014.05.004

Vermeulen, L., F De Sousa E Melo, M. Van der Heijden, K. Cameron, J.H. de Jong, T. Borovski, J.B. Tuyman, M. Todaro, C. Merz, H. Rodermond, et al. 2010. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12:468–476. http://dx.doi.org/10.1038/ncb2048

Vougiouskalaki, M., D.C. Kanelis, K. Gkouskou, and A.G. Eliopoulos. 2011. Tpl2 kinase signal transduction in inflammation and cancer. Cancer Lett. 304:80–89. http://dx.doi.org/10.1016/j.canlet.2011.02.004

Yan, X., Z. Liu, and Y. Chen. 2009. Regulation of TGF-β signaling by Smad7. Acta Biochim. Biophys. Sin. (Shanghai). 41:263–272. http://dx.doi.org/10.1093/abbs/gnp018

Yang, L., Y. Pang, and H.L. Moses. 2010. TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 31:220–227. http://dx.doi.org/10.1016/j.it.2010.04.002

Yin, J., H.H. Lee, J. Zhang, Z. Gao, Y.Y. Polotsky, and J. Ye. 2014. Regulation of hepatocyte growth factor expression by NF-κB and PPARγ in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 306:E929–E936. http://dx.doi.org/10.1152/ajpendo.00687.2013

Yucel-Lindberg, T., and G. Brunius. 2006. Epidermal growth factor synergistically enhances interleukin-8 production in human gingival fibroblasts stimulated with interleukin-1β. Arch. Oral Biol. 51:892–898. http://dx.doi.org/10.1016/j.archoralbio.2006.03.004

Zhang, J., L. Chen, M. Xiao, C. Wang, and Z. Qian. 2011. FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1–mediated macrophage infiltration and chronic inflammation. Am. J. Pathol. 178:382–390. http://dx.doi.org/10.1016/j.ajpath.2010.11.017

Zheng, B., Z. Zhang, C.M. Black, B. de Crombrugghe, and C.P. Denton. 2012. Ligand-dependent genetic recombination in fibroblasts: a potentially powerful technique for investigating gene function in fibrosis. Am. J. Pathol. 160:1669–1617. http://dx.doi.org/10.1016/S0002-9440(10)61108-X